StockWatch
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultJul 29, 2026, 07:21 AM

uniQure Q2 Net Loss $81.1M, Revenue $5.8M; Raises $242.7M in Offering

AI Summary

uniQure N.V. reported a net loss of $81.1 million for the second quarter of 2026, an increase from $37.7 million in the same period last year, with total revenues rising to $5.8 million. The company successfully completed a follow-on public offering in June 2026, generating net proceeds of $242.7 million, significantly boosting its cash and cash equivalents to $413.0 million. Additionally, uniQure amended its loan facility with Hercules Capital in July 2026, extending the availability of a $100.0 million term loan tranche.

Key Highlights

  • Net loss for the second quarter of 2026 was $81.1 million, compared to $37.7 million in Q2 2025.
  • Total revenues for the second quarter of 2026 reached $5.8 million, up from $5.3 million in Q2 2025.
  • Basic and diluted net loss per ordinary share was $1.22 for Q2 2026, versus $0.69 in Q2 2025.
  • Net proceeds of $242.7 million were raised from a follow-on public offering in June 2026.
  • Cash and cash equivalents increased to $413.0 million as of June 30, 2026, from $80.2 million at year-end 2025.
  • The loan facility with Hercules Capital was amended in July 2026, extending the draw period for a $100.0 million tranche.
  • Net cash used in operating activities decreased to $66.8 million for the six months ended June 30, 2026.